# Autolus *

**Canonical:** https://apis.io/providers/autolus/  
**Website:** https://www.autolus.com  
**APIs profiled:** 0

Autolus is a life-sciences (biopharmaceutical) company operating in the cell-therapy space, developing programmed / engineered T cell (CAR-T) therapies for cancer and other serious diseases. It was surfaced as a portfolio company of GV and added to the API Evangelist network for enrichment. As a clinical/commercial-stage biopharma, its public web presence (autolus.com) is a corporate marketing and investor-relations site rather than a developer platform: no public API, developer portal, API documentation, or OpenAPI surface was found during enrichment. The only machine-discoverable artifact is a minimal RFC 9116 security.txt.

## Kin Score — 4.4 / 100 (minimal)

Scored 2026-08-21 under rubric 0.12.0. Trend: flat (+0.0 from 4.4).

| Facet | Score |
|---|---|
| Discoverability | 61.1 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 2.6 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | yes |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Autolus Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Life Sciences, Biopharmaceutical, Biotechnology, Cell Therapy, Immunotherapy, Oncology, Cart

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/autolus/). Scores are computed from the provider's own public artifacts under a published rubric.